Free Trial
NASDAQ:TXMD

TherapeuticsMD Q3 2025 Earnings Report

TherapeuticsMD logo
$2.02 +0.01 (+0.50%)
As of 04:00 PM Eastern

TherapeuticsMD EPS Results

Actual EPS
$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TherapeuticsMD Revenue Results

Actual Revenue
$0.78 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TherapeuticsMD Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call Date
Thursday, November 6, 2025
Conference Call Time
6:00AM ET

Upcoming Earnings

TherapeuticsMD's Q3 2026 earnings is estimated for Tuesday, November 17, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

TherapeuticsMD Earnings Headlines

They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, and Millennium by 122%. Kopernik Global made it their largest holding, owning roughly 8% of the company. It holds rights to an 88 million ounce deposit with existing roads, power, and permits that never expire. Market cap sits near $4 billion against a deposit worth hundreds of billions at current gold prices.tc pixel
See More TherapeuticsMD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TherapeuticsMD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TherapeuticsMD and other key companies, straight to your email.

About TherapeuticsMD

TherapeuticsMD (NASDAQ:TXMD) was a pharmaceutical company focused on developing and commercializing products for women’s health. The company’s portfolio addressed contraception, menopause, and related reproductive-health needs, primarily in the United States.

Its principal products included ANNOVERA, a reusable vaginal contraceptive system; IMVEXXY, a vaginal estradiol insert for treating moderate-to-severe dyspareunia associated with menopause; and BIJUVA, an oral hormone therapy containing estradiol and progesterone for certain menopausal symptoms. TherapeuticsMD also developed prenatal vitamins and other products intended to support women’s health.

TherapeuticsMD was formerly publicly traded on the Nasdaq under the symbol TXMD. The company later underwent significant financial and strategic changes, including a bankruptcy restructuring and the transfer or sale of rights to certain products. Accordingly, its historical product portfolio and corporate status may differ from information associated with the former public company.

View TherapeuticsMD Profile